Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology
Joanna C. Neill, B. Terence Grayson, Béla Kiss, et al.
European Neuropsychopharmacology (2015) Vol. 26, Iss. 1, pp. 3-14
Open Access | Times Cited: 82

Showing 1-25 of 82 citing articles:

Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial
György Németh, I. Laszlovszky, Pál Czobor, et al.
The Lancet (2017) Vol. 389, Iss. 10074, pp. 1103-1113
Closed Access | Times Cited: 306
The dopamine D3 receptor, a quarter century later
Pierre Sokoloff, Bernard Le Foll
European Journal of Neuroscience (2016) Vol. 45, Iss. 1, pp. 2-19
Open Access | Times Cited: 197
NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update
Daniela Cadinu, B. Terence Grayson, Giovanni Podda, et al.
Neuropharmacology (2017) Vol. 142, pp. 41-62
Open Access | Times Cited: 145
Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole
Joshua S. Frankel, Thomas L. Schwartz
Therapeutic Advances in Psychopharmacology (2016) Vol. 7, Iss. 1, pp. 29-41
Open Access | Times Cited: 109
Current drug treatments targeting dopamine D3 receptor
Gian Marco Leggio, Claudio Bucolo, Chiara Bianca Maria Platania, et al.
Pharmacology & Therapeutics (2016) Vol. 165, pp. 164-177
Closed Access | Times Cited: 98
The efficacy of cariprazine on cognition: a post hoc analysis from phase II/III clinical trials in bipolar mania, bipolar depression, and schizophrenia
Roger S. McIntyre, David G. Daniel, Eduard Vieta, et al.
CNS Spectrums (2022) Vol. 28, Iss. 3, pp. 319-330
Open Access | Times Cited: 44
Overview of Novel Antipsychotic Drugs: State of the Art, New Mechanisms, and Clinical Aspects of Promising Compounds
Letizia Biso, Marco Carli, Marco Scarselli, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 85-85
Open Access | Times Cited: 1
Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model
Vanja Đurić, Mounira Banasr, Tina Franklin, et al.
The International Journal of Neuropsychopharmacology (2017) Vol. 20, Iss. 10, pp. 788-796
Open Access | Times Cited: 86
A Fe3O4@SiO2/Schiff Base/Pd Complex as an Efficient Heterogeneous and Recyclable Nanocatalyst for One‐Pot Domino Synthesis of Carbamates and Unsymmetrical Ureas
Iman Dindarloo Inaloo, Sahar Majnooni
European Journal of Organic Chemistry (2019) Vol. 2019, Iss. 37, pp. 6359-6368
Closed Access | Times Cited: 67
Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders
Béla Kiss, I. Laszlovszky, Balázs Krámos, et al.
Biomolecules (2021) Vol. 11, Iss. 1, pp. 104-104
Open Access | Times Cited: 51
Sex difference alters the behavioral and cognitive performance in a rat model of schizophrenia induced by sub-chronic ketamine
Mohammad-Ali Samizadeh, Seyedeh-Tabassom Abdollahi-Keyvani, Hamed Fallah, et al.
Journal of Psychiatric Research (2024) Vol. 178, pp. 180-187
Closed Access | Times Cited: 6
The dopamine D 3 -preferring D 2 /D 3 dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia
David J. Watson, Madeleine V. King, István Gyertyán, et al.
European Neuropsychopharmacology (2015) Vol. 26, Iss. 2, pp. 208-224
Closed Access | Times Cited: 61
Crosstalk between endoplasmic reticulum stress and oxidative stress in schizophrenia: The dawn of new therapeutic approaches
Shivangi Patel, Dilip Sharma, Kiran Kalia, et al.
Neuroscience & Biobehavioral Reviews (2017) Vol. 83, pp. 589-603
Closed Access | Times Cited: 59
The role of dopamine D3receptors in the mechanism of action of cariprazine
Francesca Calabrese, Frank I. Tarazi, Giorgio Racagni, et al.
CNS Spectrums (2019) Vol. 25, Iss. 3, pp. 343-351
Open Access | Times Cited: 52
Cariprazine: A Review in Schizophrenia
Karly P. Garnock-Jones
CNS Drugs (2017) Vol. 31, Iss. 6, pp. 513-525
Closed Access | Times Cited: 51
Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies
Stephen R. Marder, W. Wolfgang Fleischhacker, Willie Earley, et al.
European Neuropsychopharmacology (2018) Vol. 29, Iss. 1, pp. 127-136
Open Access | Times Cited: 45
Managing Negative Symptoms of Schizophrenia: How Far Have We Come?
Joshua T. Kantrowitz
CNS Drugs (2017) Vol. 31, Iss. 5, pp. 373-388
Closed Access | Times Cited: 44
Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
Leslie Citrome
Neuropsychiatric Disease and Treatment (2018) Vol. Volume 14, pp. 2563-2577
Open Access | Times Cited: 42
Effects of cariprazine on extracellular levels of glutamate, GABA, dopamine, noradrenaline and serotonin in the medial prefrontal cortex in the rat phencyclidine model of schizophrenia studied by microdialysis and simultaneous recordings of locomotor activity
Ján Kehr, Takashi Yoshitake, Fumio Ichinose, et al.
Psychopharmacology (2018) Vol. 235, Iss. 5, pp. 1593-1607
Open Access | Times Cited: 41
Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments
Sebastiano Alfio Torrisi, Samuele Laudani, Gabriella Contarini, et al.
Pharmaceuticals (2020) Vol. 13, Iss. 11, pp. 365-365
Open Access | Times Cited: 35
Cariprazine: an augmentation strategy for treatment-resistant schizophrenia with pro-cognitive and anti-hostility effects
Chelsea Boydstun, Sean Lynch, Patrick DiGenova
International Clinical Psychopharmacology (2023) Vol. 38, Iss. 5, pp. 361-366
Closed Access | Times Cited: 11
Effect of cariprazine on attention and quality of life in patients with predominant negative symptoms of schizophrenia: A post-hoc analysis
Oloruntoba Oluboka, Andrea Bardell, Howard C. Margolese, et al.
Schizophrenia Research Cognition (2025) Vol. 40, pp. 100355-100355
Closed Access
Dopaminergic mechanisms in memory consolidation and antidepressant reversal of a chronic mild stress-induced cognitive impairment`
Mariusz Papp, Piotr Gruca, Magdalena Łasoń, et al.
Psychopharmacology (2017) Vol. 234, Iss. 17, pp. 2571-2585
Open Access | Times Cited: 38
Maternal behaviours and adult offspring behavioural deficits are predicted by maternal TNFα concentration in a rat model of neurodevelopmental disorders
Harry G. Potter, Hager M. Kowash, Rebecca M. Woods, et al.
Brain Behavior and Immunity (2022) Vol. 108, pp. 162-175
Open Access | Times Cited: 18
Vortioxetine improved negative and cognitive symptoms of schizophrenia in subchronic MK-801 model in rats
Nuh Mehmet Bozkurt, Gökhan Ünal
Behavioural Brain Research (2023) Vol. 444, pp. 114365-114365
Closed Access | Times Cited: 10
Page 1 - Next Page

Scroll to top